Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194754 | 1.00 | ACE (0.50) | ACERENLMNACYP2C19HSD17B10 | |
| Hydrochloric Acid SCHEMBL3188591 | 0.98 | ACE (0.49) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL163319 | 0.83 | LMNA (0.54) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL1442233 | 0.83 | LMNA (0.54) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL30305374 | 0.83 | LMNA (0.54) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL2927893 | 0.83 | LMNA (0.54) | ACERENLMNACYP2C19HSD17B10 | |
| Hydrochloric Acid SCHEMBL951618 | 0.82 | LMNA (0.53) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL2679460 | 0.80 | ACE (0.50) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL212486 | 0.80 | ACE (0.50) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL9389379 | 0.80 | ACE (0.50) | ACERENLMNACYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169295-B2 | Macrocycles and macrocycle stabilized peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| EP-2627662-B1 | METHODS FOR PREPARING MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20130281657-A1 | MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-24 | — | — | US | disclosed |
| EP-2627662-A1 | METHODS FOR PREPARING MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | Bristol-Myers Squibb Company (US) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012051405-A1 | METHODS FOR PREPARING MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2005097783-A1 | THIOCARBAMOYLPROLINES | MERCK PATENT GMBH (DE) | 2005-10-20 | — | — | WO | disclosed |
| EP-1001762-A4 | METHOD OF USING NEUROTROPHIC CARBAMATES AND UREAS | GUILFORD PHARM INC (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1001762-A1 | METHOD OF USING NEUROTROPHIC CARBAMATES AND UREAS | GPI NIL Holdings, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1998037882-A1 | METHOD OF USING NEUROTROPHIC CARBAMATES AND UREAS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281657-A1 | MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | PTMS, VIP, MTPN | ACE 1283/4885REN 1517/4885LMNA 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.